Etrasimod is a medicine used to treat ulcerative colitis, a disease that causes swelling and sores in the large intestine. It is a pill taken once a day. It works by keeping some immune cells from reaching the gut, which calms the swelling.
Every report comes from a Lived member, sent anonymously.
Have you tried Velsipity (Etrasimod) for Ulcerative Colitis?
Etrasimod, sold as Velsipity, is a prescription tablet for adults with moderately to severely active ulcerative colitis, a long-term inflammatory disease of the large intestine that causes diarrhea, rectal bleeding and urgent trips to the bathroom. It is used when colitis needs more than the standard first steps, such as aminosalicylates or steroids, and it is not approved for children. Etrasimod belongs to a newer group of oral medicines called sphingosine 1-phosphate (S1P) receptor modulators; the other one approved for ulcerative colitis is ozanimod (Zeposia). Doctors count these among the advanced therapies for colitis, alongside biologic injections or infusions and JAK (Janus kinase) inhibitor tablets. The American Gastroenterological Association's 2024 guideline places etrasimod among the more effective choices for people who have not yet tried an advanced therapy, but among the less effective ones for people whose colitis has already been treated with one, particularly a tumor necrosis factor (TNF) blocker.
Lymphocytes are white blood cells that drive much of the inflammation in ulcerative colitis. They normally leave the lymph nodes, travel in the bloodstream and settle in tissues such as the lining of the colon. To leave the lymph nodes, they rely on signals received through S1P receptors on their surface. Etrasimod binds to those receptors and partly blocks this exit, so more lymphocytes stay in the lymph nodes and fewer circulate. Fewer are then thought to reach the gut, which allows the inflammation to settle. During treatment, blood lymphocyte counts fall to a little under half of their starting level; the effect is reversible, and counts usually return to normal within 4 to 5 weeks of stopping. Researchers do not know exactly how this calms colitis, and the medicine controls the disease rather than curing it.
Velsipity is a 2 mg tablet taken once a day, swallowed whole, with or without food. The same dose is used from the first day. If a dose is missed, take the next one at the usual time; do not take two to make up for it. Several checks come before the first dose: a recent blood count, liver blood tests, an electrocardiogram (ECG, a quick tracing of the heart's electrical rhythm), an eye exam that looks at the macula (the center of the retina, responsible for sharp central vision) and a skin check. People with no confirmed history of chickenpox or full chickenpox vaccination are tested for immunity, and if they are not immune they are vaccinated first and then wait 4 weeks before starting. Other vaccines are best brought up to date beforehand, because vaccines may work less well during treatment. An active infection is treated before etrasimod begins.
Headache, dizziness and raised liver enzymes on blood tests were the most common side effects in trials, followed by joint pain, nausea, slightly higher blood pressure and cholesterol, and urinary tract infections. On the first day or two the heart rate can dip a little. Most people feel nothing, but dizziness, lightheadedness, a slow or skipping heartbeat, shortness of breath or chest pain should be reported to the prescriber. Because etrasimod keeps immune cells out of circulation, infections are more likely, including shingles and other herpes infections. The risk lasts throughout treatment and for about 5 weeks after the last dose. Call the care team right away for a fever, flu-like illness, burning or frequent urination, or a headache with fever, stiff neck, sensitivity to light or confusion, which can signal meningitis. A few serious problems are uncommon but worth recognizing. Liver injury can show up as unexplained nausea or vomiting, stomach pain, loss of appetite, yellowing of the skin or eyes, or dark urine; report these right away. Macular edema, swelling at the center of the retina, can cause blurred or shadowed central vision, a blind spot or oddly colored vision. It needs prompt assessment, because swelling that persists for months can permanently harm vision. A rare brain condition called posterior reversible encephalopathy syndrome (PRES) can cause a sudden severe headache, confusion, vision disturbance or a seizure; these need immediate medical attention. New or worsening shortness of breath should also be reported, since etrasimod can slightly reduce lung function.
Etrasimod is not used by anyone who, in the past 6 months, has had a heart attack, unstable angina (new or worsening chest pain, including at rest), a stroke or ministroke, or heart failure serious enough to need hospital care or to limit ordinary activity. It is also ruled out for certain heart rhythm conduction problems (Mobitz type II second-degree or third-degree heart block, or sick sinus syndrome) unless a working pacemaker is in place. People with a very slow resting heart rate, repeated fainting, untreated severe sleep apnea, uncontrolled high blood pressure or other heart conditions may need a cardiologist's opinion before starting. A handful of medicines change the decision. Fluconazole, an antifungal, raises etrasimod levels, and rifampin, an antibiotic used for tuberculosis, lowers them; neither combination is recommended. Heart rhythm drugs such as amiodarone or sotalol, other medicines that prolong the QT interval (the part of an ECG that shows how long the heart takes to reset between beats), and starting a beta blocker or calcium channel blocker during treatment all call for cardiology advice first. Other immune-suppressing medicines, apart from steroids, are generally not combined with etrasimod, and switching from a long-acting one needs planning to avoid overlapping effects. Live vaccines should be avoided during treatment and for 5 weeks afterward; any that are needed are given at least 4 weeks before starting. Based on animal studies, etrasimod may harm a developing baby. People who could become pregnant should use effective contraception during treatment and for one week after stopping, and tell the prescriber promptly about a pregnancy. It is not known whether etrasimod passes into breast milk. Medicines in this class have been linked to a higher risk of skin cancer, including melanoma, so a skin check near the start and periodically, sun protection, and a prompt look at any new or changing spot are advised.
Some people notice fewer bowel movements within the first two weeks and less bleeding within about a month, but whether the medicine is working is usually judged at around 12 weeks. In the main year-long trial, 27% of people taking etrasimod were in remission at 12 weeks compared with 7% on a placebo (dummy pill), and 32% compared with 7% at one year. Remission here meant near-normal stool frequency, no rectal bleeding and a largely healed colon lining on colonoscopy. More people improved without reaching full remission: in a 12-week trial, 62% had a meaningful response compared with 41% on placebo. Results were smaller in people whose colitis had already been treated with a biologic or JAK inhibitor. For people who respond, etrasimod is taken every day as ongoing maintenance. Follow-up includes blood pressure checks, periodic eye exams and skin checks, and blood tests as the care team advises, including liver tests if symptoms suggest a problem. Stopping is best planned with the gastroenterologist, because the immune effect lingers for about 4 to 5 weeks and affects when another treatment can safely begin.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Velsipity (Etrasimod), what you've noticed, or ask the community a question.